The estimated Net Worth of Mark E Saad is at least $2.18 millió dollars as of 11 September 2024. Mr. Saad owns over 11,016 units of Axsome Therapeutics Inc stock worth over $1,913,269 and over the last 19 years he sold AXSM stock worth over $0. In addition, he makes $265,310 as Independent Director at Axsome Therapeutics Inc.
Sign up
Mr. Saad AXSM stock SEC Form 4 insiders trading
Mark has made over 13 trades of the Axsome Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 11,016 units of AXSM stock worth $40,429 on 11 September 2024.
The largest trade he's ever made was buying 15,000 units of Axsome Therapeutics Inc stock on 12 August 2008 worth over $100,350. On average, Mark trades about 1,453 units every 143 days since 2006. As of 11 September 2024 he still owns at least 21,018 units of Axsome Therapeutics Inc stock.
You can see the complete history of Mr. Saad stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Saad biography
Mark E. Saad serves as Independent Director of the Company. Mr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2017, he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Previously, he served as Chief Financial Officer of Cytori Therapeutics from 2004 to 2014, where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the Chief Operating Officer of the Global Healthcare Group. Prior to UBS, he was part of the Health Care Investment Banking Group at Salomon Smith Barney.
What is the salary of Mark Saad?
As the Independent Director of Axsome Therapeutics Inc, the total compensation of Mark Saad at Axsome Therapeutics Inc is $265,310. There are 7 executives at Axsome Therapeutics Inc getting paid more, with Herriot Tabuteau having the highest compensation of $4,715,750.
How old is Mark Saad?
Mark Saad is 50, he's been the Independent Director of Axsome Therapeutics Inc since 2014. There are 4 older and 9 younger executives at Axsome Therapeutics Inc. The oldest executive at Axsome Therapeutics Inc is David Marek, 55, who is the Chief Commercial Officer.
What's Mark Saad's mailing address?
Mark's mailing address filed with the SEC is C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY, 10007.
Insiders trading at Axsome Therapeutics Inc
Over the last 9 years, insiders at Axsome Therapeutics Inc have traded over $3,013,485 worth of Axsome Therapeutics Inc stock and bought 82,512 units worth $1,366,003 . The most active insiders traders include Roger Jeffs, Susan Mahony és Mark Coleman. On average, Axsome Therapeutics Inc executives and independent directors trade stock every 114 days with the average trade being worth of $1,405,685. The most recent stock trade was executed by Mark E Saad on 11 September 2024, trading 11,016 units of AXSM stock currently worth $40,429.
What does Axsome Therapeutics Inc do?
axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
What does Axsome Therapeutics Inc's logo look like?
Complete history of Mr. Saad stock trades at Axsome Therapeutics Inc és Catheter Precision
Axsome Therapeutics Inc executives and stock owners
Axsome Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Herriot Tabuteau,
Chairman of the Board, President, Chief Executive Officer, Founder -
David Marek,
Chief Commercial Officer -
Nick Pizzie,
Chief Financial Officer -
Dr. Herriot Tabuteau M.D.,
Founder, Chairman, CEO & Pres -
Mark L. Jacobson,
COO & Sec. -
Nick Pizzie CPA, M.B.A.,
Chief Financial Officer -
Roger Jeffs,
Lead Independent Director -
Mark Saad,
Independent Director -
Mark Coleman,
Independent Director -
Amanda Jones,
Senior Vice President - Clinical Research -
Cedric O'Gorman,
Senior Vice President - Clinical Development and Medical Affairs -
Mark Jacobson,
Chief Operating Officer -
Joseph Debrah-Afful CPA, M.B.A.,
Director of Fin. -
Kevin Laliberte Pharm.D.,
Exec. VP of Product Strategy -
Lori Englebert M.B.A.,
Sr. VP of Commercial & Bus. Devel. -
Dr. Amanda Jones Pharm.D.,
Sr. VP of Clinical Devel. -
Constance Ames,
Vice President, Finance -
Myrtle S Potter,
Director -
Randall Kaye,
Chief Medical Officer -
Hunter R. Murdock,
General Counsel -
John Golubieski,
Chief Financial Officer -
Susan Mahony,